Purpose: To evaluate the safety and efficacy of a novel optical coherence tomography (OCT)-guided atherectomy catheter in treating patients with symptomatic femoropopliteal disease. Methods: The VISION trial (ClinicalTrials.gov identifier NCT01937351) was a single-arm, multicenter, global investigational device exemption study enrolling 158 subjects (mean age 67.2±10.5 years; 87 men) across 20 participating sites. In this cohort, 198 lesions were treated with an average length of 53±40 mm using the Pantheris catheter alone or Pantheris + adjunctive therapy. The primary safety endpoint was the composite of major adverse events (MAEs) through 6 months (objective performance goal 43.2%). Technical success (primary efficacy outcome) was defined as the percent of target lesions with a residual diameter stenosis ≤50% after treatment with the Pantheris device alone (objective performance goal 87.0%). Procedural success was defined as reduction in stenosis to ≤30% after Pantheris ± adjunctive therapy. Tissue specimens retrieved from each treated lesion were histologically analyzed to evaluate the accuracy and precision of OCT image guidance. Results: The primary efficacy outcome was achieved in 192 (97.0%) of the 198 lesions treated with the Pantheris catheter. Across all lesions, mean diameter stenosis was reduced from 78.7%±15.1% at baseline to 30.3%±11.8% after Pantheris alone (p<0.001) and to 22.4%±9.9% after Pantheris ± adjunctive therapy (p<0.001). Of the 198 target lesions, 104 (52.5%) were treated with the Pantheris alone, 84 (42.4%) were treated with Pantheris + adjunctive angioplasty, and 10 (5.1%) with Pantheris + angioplasty + stenting. The composite MAE outcome through 6 months occurred in 25 (16.6%) of 151 subjects. There were no clinically significant perforations, 1 (0.5%) catheter-related dissection, 4 (2%) embolic events, and a 6.4% clinically driven target lesion revascularization rate at 6 months. The 40-lesion chronic total occlusion (CTO) subset (mean lesion length 82±38 mm) achieved a similar significant reduction in stenosis to 35.5%±13.6% after Pantheris alone (p<0.001). Histological analysis of atherectomy specimens confirmed <1% adventitia in 82.1% of the samples, highlighting the precision of OCT guidance. Characterization of the OCT-guided lesions revealed evidence of an underestimation of disease burden when using fluoroscopy. Conclusion: OCT-guided atherectomy for femoropopliteal disease is safe and effective. Additionally, the precision afforded by OCT guidance leads to greater removal of plaque during atherectomy while sparing the adventitia.
Introduction
Peripheral artery disease (PAD) is a significant public health problem, costing more than US$21 billion annually and representing a major source of morbidity and mortality across the United States. 1, 2 To date, of the 27 million PAD patients in the United States and Europe, ~500 000 require revascularization each year. 3 Within the spectrum of PAD, superficial femoral artery (SFA) disease is the leading cause of ischemic leg pain, decline in ambulatory function, and tissue breakdown requiring revascularization. 4, 5 Endovascular strategies have become the front-line therapy for the majority of these procedures. 6 Unlike the direct visualization of open surgery, the 2-dimensional fluoroscopic guidance used for endovascular intervention restricts treatments to contrast-apparent stenosis, limiting appreciation of vessel tortuosity and intraluminal plaque eccentricity. As a consequence of this constraint, endovascular procedures may result in residual plaque burden, dissections, or perforations. 7, 8 Tarricone et al 9 demonstrated that fluoroscopy-guided directional atherectomy (DA) leads to significant rates of iatrogenic arterial wall damage (adventitial disruption), which may trigger inflammatory cascades that accelerate restenosis.
In an attempt to improve PAD therapies, physicians are increasingly using optical coherence tomography (OCT) for the diagnosis, localization, and characterization of plaque burden and to gauge optimal therapeutic endpoints. [10] [11] [12] [13] OCT, with 10 times the resolution of intravascular ultrasound, allows physicians to clearly interpret and discern between structures in healthy and diseased tissues. Accordingly, in PAD, OCT has been used both longitudinally to diagnose overall plaque burden as well as axially to define focal plaque eccentricities. 10, 13 From a safety standpoint, OCT is a lightbased imaging source that does not require contrast 14 or fluoroscopic radiation, which may expand the imaging options to patients with renal insufficiency. Likewise, with an increased incidence of hazardous radiation for interventional healthcare providers, OCT may reduce radiation dosage and exposure.
The major limitation to this technique is that physicians have not been able to directly apply OCT visualization in real time to guide therapy. The need for real-time intravascular OCT visualization at the point of therapy led to the development of the Pantheris atherectomy system (Avinger, Redwood City, CA, USA). For the first time, diagnostic imaging via OCT has been incorporated directly onto a therapeutic DA catheter to facilitate accurate assessment of disease location, morphology, and vessel structures for intravascular intervention.
A trial to assess the safety, efficacy, and precision of the Pantheris OCT-guided atherectomy catheter when treating femoropopliteal lesions was designed to test the hypothesis that OCT guidance would allow optimal plaque debulking for revascularization while minimizing damage to the adventitial borders, reducing dissections and/or perforations. Atherectomy tissue specimens from each treated lesion were retrieved and histologically analyzed for their specific composition in order to validate the accuracy and precision of OCT image guidance.
Methods

Study Design
VISION (EValuatIon of the PantheriS OptIcal COherence
Tomography ImagiNg Atherectomy System for use in the peripheral vasculature) was a prospective, single-arm, multicenter investigational device exemption trial designed to evaluate the safety and effectiveness of the Pantheris system to excise plaque from the superficial femoral (SFA) and popliteal arteries using OCT-assisted orientation as an adjunct to fluoroscopy. All 20 investigative sites (19 United States, 1 European Union) obtained approval from their institutional review board or ethics committee prior to enrolling subjects in the study. All angiography data was reviewed by an independent core laboratory (SynvaCor, Springfield, IL, USA), while major adverse events (MAEs) were adjudicated by an independent clinical events committee (Prairie Education and Research Cooperative, Springfield, IL, USA). The trial was registered on the National Institutes of Health website (ClinicalTrials.gov identifier NCT0193735).
Device Description
The Pantheris system used in the VISION trial consists of 4 components: the Pantheris catheter, occlusion sheath, imaging sled, and lightbox console. The Pantheris catheter is 135 cm long and incorporates a 155-µm optical fiber for OCT functionality; it is compatible with 7-F and 8-F sheaths and operates using a 0.014-inch rapid exchange wire lumen. The OCT laser aperture is located 1.2 mm proximal to the cutting edge. The OCT is a swept source laser utilizing frequency domain via common-path interferometry. The catheter tip is made of a flexible nosecone, rotating cutter blade with internal OCT fiber, and an apposition balloon inferior to the cutting window ( Figure 1) . The nosecone provides space to pack excised plaque and tissue. The catheter handle assembly consists of a user slide button, shaft rotation torque knob, flush lumen, balloon inflation lumen, and an optical connector.
Inclusion/Exclusion Criteria
All subjects undergoing evaluation for lower extremity revascularization at the participating centers between July 2014 and March 2015 were screened. Key study inclusion criteria included de novo stenosis ≥70% (investigator assessed via fluoroscopy), reference vessel diameter ≥3.0 and ≤7.0 mm, lesion length ≤150 mm, and ≥1 patent runoff vessel. Exclusion criteria included moderate to severe calcification, target lesion within a graft or in the iliac artery, in-stent restenosis, and acute ischemia and/or acute thrombosis.
Protocol for Atherectomy Procedures and Histology
Investigators accessed a treatment site using standard techniques for a contralateral or antegrade approach and initiated systemic anticoagulation according to local protocols. Patients were enrolled on successful chronic total occlusion (CTO) crossing and/or luminal wire placement distal to the target lesions. CTO crossing in the true lumen was preferentially performed using the OCT-guided Ocelot catheter (Avinger Inc). The use of an embolic protection device was recommended.
The Pantheris catheter was advanced through the sheath to the proximal segment of the target lesion. Investigators used OCT to identify plaque location, orient the cutter, and guide depth of cut during advancement of the catheter. Following atherectomy, operators used OCT for qualitative plaque assessment and OCT combined with angiography to assess residual plaque burden to guide further debulking prior to case completion. On average, a single device insertion would yield between 5 and 10 cutting passes through the lesion prior to removal. Across all lesions, 1.7 catheter insertions with nosecone cleaning were required on average to satisfy efficacy endpoints. Further adjunctive therapy following atherectomy and dual antiplatelet therapy after the procedure were at the discretion of each operator.
Because the directional cutter of the Pantheris catheter is aimed using OCT to guide plaque removal with avoidance of arterial wall structures (Figure 2 ), all plaque captured per lesion was collected and preserved for histopathologic analysis. The tissue was formalin fixed according to standard methodology and stained with hematoxylin-eosin, Gomori's trichrome, and elastic Van Gieson stains. The stained histological slides were scanned and converted into digital images using a slide scanner (ScanScope CS; Aperio, Vista, CA, USA). Quantification was performed with ScanScope analysis tools.
Patient Assessment
Baseline values for ankle-brachial index (ABI) and Rutherford classification were obtained before the procedure. Prior to discharge, subjects were evaluated for any adverse events, and the ABI was measured. Follow-up clinic visits were scheduled at 30 days and 6 months to monitor any adverse events and to assess ABI, Rutherford category, and quality of life (QoL) measurements. The need for angiographic evaluation and therapeutic reintervention were driven by investigator assessment of clinical symptomatology in combination with ABI and Rutherford classification in the follow-up period.
Study Enrollment
The VISION trial enrolled 158 subjects (mean age 67.2±10.5 years; 87 men) with 198 lesions in both the perprotocol (n=130) and roll-in (n=28) cohorts ( Figure 3 ). The majority of subjects (118, 74.7%) had 1 target lesion treated; the remainder (40, 25.3%) had 2 lesions treated. Complete baseline demographics, comorbidities, and lesion characteristics as assessed by the angiographic core laboratory are provided in Table 1 . Per the adjudicated data, 160 (80.8%) of the 198 target lesions were in the SFA. Mean stenosis was 78.7%±15.1%, and mean lesion length (via fluoroscopy) was 53±40 mm. Forty (20.2%) of 198 lesions were CTOs.
Study Outcomes and Definitions
Technical success, the primary effectiveness endpoint, was defined as the percent of lesions with a residual diameter stenosis ≤50% after treatment with the Pantheris catheter alone. The primary safety endpoint was based on subjects free from a composite of MAEs through 6 months, including cardiovascular-related death, major index limb amputation, clinically driven target lesion revascularization (TLR), myocardial infarction, and device-related events (pseudoaneurysm, clinically significant perforation, dissection, or embolism).
Procedural success, a secondary effectiveness endpoint, was defined as the percent of lesions with residual stenosis ≤30% after Pantheris ± adjunctive therapy. Additional secondary effectiveness outcomes included ABI, Rutherford classification, and QoL measurements using both SF-12 and VascuQoL questionnaires.
The distances between proximal and distal plaque excision sites of individual lesions were measured to examine any differences between the diagnostic lesion length based on fluoroscopy and the OCT-guided treatment length afforded by the Pantheris catheter. These "diagnostic gap" values were then compared in TLR lesions vs stenosed lesions.
Given that the participating physicians were first-time users of this OCT-guided atherectomy device, learning curve metrics were utilized to determine if treated lesion length using OCT, adventitial injury, TLR rates, and radiation exposure correlated with physician experience.
Statistical Analysis
Continuous data are presented as the means ± standard deviation (counts/sample); categorical data are given as the count/sample (percentage). Primary effectiveness and safety endpoints were analyzed using Wilson's score approximation. To meet the primary safety endpoint, the 1-sided 95% upper confidence bound of the composite MAE rate through 6 months had to be less than the objective performance goal (OPG) of 43.2%. To meet the primary effectiveness endpoint, the 1-sided 95% lower confidence bound for the percent of treated lesions with ≤50% residual stenosis post-Pantheris alone had to be greater than the OPG of 87.0%. To achieve 85% power using a 1-sided alpha of 0.05, the sample size for efficacy was 127 lesions and the sample size for safety was 119 subjects. Based on the safety sample size and adjusting for ~12% lost to follow-up, at least 133 subjects had to be enrolled in this study.
The Rutherford classification at 30 days and 6 months were compared to baseline using Bowker's test for matched data. Changes in ABI and QoL scores (SP-12 and VascuQoL) at the same time points were compared using a paired t test. Clinical outcomes and plaque histology assessment data were compared between stenoses and occlusions using an unpaired t test (continuous data) and a chi-square test (categorical data). Statistical analyses were performed using SAS statistical software (version 9.3; SAS Institute, Inc, Cary, NC, USA). 
Results
Efficacy Outcomes
Technical success, the primary efficacy endpoint, was achieved in 192 (97.0%) of the 198 lesions treated with the Pantheris catheter with a 95% 1-sided lower confidence bound of 94.2%, which was above the prespecified OPG of 87.0%. Across all lesions, mean diameter stenosis was reduced from 78.7%±15.1% at baseline to 30.3%±11.8% post-Pantheris alone (p<0.001) and to 22.4%±9.9% after Pantheris ± adjunctive therapy (p<0.001). Of the 198 target lesions, 104 (52.5%) were treated with the Pantheris alone (no adjunctive treatment), 84 (42.4%) were treated with the Pantheris + adjunctive angioplasty, and 10 (5.1%) with Pantheris + angioplasty + stenting (Table 2 ). An embolic protection device was used in 70% of procedures. Statistically significant reductions (p<0.001) in stenosis were achieved in all treatment groups (Table 2) .
Safety Outcomes
The composite MAE through 6 months occurred in 25 (16.6%) of 151 subjects (Table 2) , with a 95% 1-sided upper confidence bound of 22.1%, well below the 43.2% OPG. As adjudicated by the CEC, all reported deaths through 6 months were unrelated to the Pantheris system. Six subjects experienced a total of 7 device-related events, including 4 clinically significant emboli and 1 clinically significant dissection related to the Pantheris catheter. Additionally, 1 clinically significant dissection and 1 pseudoaneurysm were related to the balloon occlusion sheath used during the procedure. No perforations were reported. Seven subjects were excluded from final analysis at 6 months: 6 withdrew or were lost to follow-up and 1 died of a non-cardiovascular-related cause. The 6-month clinically driven TLR rate was 6.4% (12/188) in all lesions, 7.9% (12/151) in all subjects, and 7.9% (3/38) in CTO lesions. ABI and Rutherford classification (Table 3) were significantly improved (p<0.001) at 30 days and 6 months when compared to baseline. An improvement in Rutherford category was observed in 120 of 144 subjects with matched data (83.3%) at baseline and 6 months (p<0.001). The overall VascuQoL score and the SF-12 QoL physical component score (Table 3) were also significantly improved at 6 months when compared to baseline (p<0.001).
Histological Validation of OCT Guidance and Subgroup Analyses
Tissue was collected from 196 of the 198 lesions treated, but 2 samples were not available for subgroup analysis. Histological examination ( Figure 4A ) of the 194 lesion tissue samples identified 121 (62.4%) with 0% adventitia and 159 (81.9%) with <1% adventitia (Figure 4B ), confirming the precision of OCT to delineate the borders between plaque and arterial walls.
In the CTO subset, the majority (38/40) of lesions were crossed in the true lumen using the OCT-guided Ocelot catheter. CTO crossing ( Figure 5A ) was followed by OCTguided atherectomy with the Pantheris catheter ( Figure 5B ). Overall, fluoroscopic lesion length (82 vs 46 mm, p<0.001) and plaque burden (total tissue excised, 110.4 vs 58.4 mg, p<0.001) were considerably higher in the CTO cohort vs stenotic lesions (Table 4) . Histological analysis corroborated no further increase in adventitial disruption (0.8 vs 1.0, p=0.78). Freedom from TLR in CTO and stenotic lesions were comparable at 92.1% vs 93.9% (p=0.71).
As demonstrated in Figure 6A , the OCT-guided treatment lengths (n=198) were significantly longer than the fluoroscopy-determined lesion lengths (72.4 vs 53.1 mm; p<0.001). Both imaging lengths were adjudicated by the core laboratory. An exemplary case in Figure 7 highlights this diagnostic discrepancy, which demonstrates plaque burden evident by OCT beyond the suggested fluoroscopy target lesion boundaries. As presented in Figure 6B , even with a low overall TLR rate (6.4%, 12/188 lesions), the TLR incidence tended to decrease when treating beyond fluoroscopy lesion boundaries by using OCTguided length (p=0.15).
Physician Learning Curve
With experience, individual physicians treated longer lesions ( Figure 8A ; p=0.155), with nonsignificant decreases in adventitial injury ( Figure 8B ; p=0.287), TLR at 6 months ( Figure 8C ; p=0.216), and total procedure radiation time ( Figure 8D ; p=0.311). 
Discussion
The VISION study evaluating the novel OCT-guided Pantheris atherectomy device in SFA and popliteal lesions met its primary efficacy endpoint, significantly reducing stenosis after Pantheris alone. The study also met its primary safety endpoint with only 1 dissection and 0 perforations across all lesion types and with a low clinically driven 6-month TLR rate. Functional outcomes were significantly improved at 6 months. Additionally, histological analysis of the excised tissues confirmed the precision of OCT guidance based on 82.1% of lesions with <1% of adventitia by area found in the tissue samples. These results led to the recent Food and Drug Administration approval of Pantheris, the first combination imaging and therapeutic catheter. The VISION study clearly demonstrated the efficacy of OCT-guided atherectomy by reducing stenosis 66% after Pantheris treatment alone, with comparable efficacy in CTOs. The reduction in stenosis after Pantheris alone was increased to 86% with the use of adjunctive therapies that included mainly angioplasty and minimal stenting. Overall, the OCT-guided DA luminal gain is favorable when compared with other fluoroscopy-guided directional and rotational atherectomy devices. [15] [16] [17] 
Procedure Benefits of OCT Guidance
Numerous single-arm registries and studies have reported suboptimal outcomes for fluoroscopy-guided DA. For example, the TALON registry consisted of 601 patients treated with the SilverHawk (Medtronic, Dublin, Ireland) DA device, reporting 10% TLR at 6 months and 20% TLR at 12 months, with primary patency of 80% at 12 months. 18 More recently, DEFINITIVE LE, which evaluated 799 patients treated under angiographic guidance with the SilverHawk and TurboHawk DA systems, reported a technical success of 74.9%, primary patency of 78% for all lesions, and primary patency of 65% in the CTO cohort at 12-months. 19 Clinically driven TLR was not evaluated. While most DA procedures are able to achieve luminal gain, the most significant point is that luminal gain in VISION was obtained largely through plaque-only debulking, with <1% adventitia measured in atherectomy specimens. This is in stark contrast to peripheral DA where a recent study found that specimens contained a mean of 16% adventitia following TurboHawk DA. 20 Tarricone et al 9 further corroborated adventitial disruption with a loss of patency and lesion reocclusion in 97% of patients whose DA samples contained adventitia and media (n=62) vs 11% in those that did not (n=54). These more recent studies highlight the incremental benefit of OCT guidance, where direct identification and avoidance of adventitial disruption during atherectomy may improve midterm patency and reduce revascularization risk. Indeed, the zero perforation and <1% dissection rates achieved with the Pantheris catheter are impressive compared with the DEFINITIVE LE study, which reported 5.2% perforation and 2.3% dissection rates. 19 With regard to adjunctive therapy, OCT guidance proved helpful in precisely identifying short segments where residual plaque burden, medial calcification, or flow disturbances supported adjunctive angioplasty and stent placement. The ability to utilize OCT to dictate adjunctive therapy may be advantageous, as recent evidence has shown that when stenting is required in the SFA, the use of short stents (spot stenting) significantly improves patency compared with stents ≥10 cm. 21 Using OCT guidance during DA in the VISION study limited both the frequency and size of SFA stent placement; overall, 8 of 156 stenosed lesions and 2 of 40 CTOs required adjunctive stent therapy, the latter a dramatic reduction from the 67% stent rate reported in SFA CTO therapy. 21 The VISION study validated both CTO crossing and subsequent therapy as true lumen using both OCT and histological analysis of atherectomy specimens. Previous studies looking at true lumen CTO crossing benefits did not evaluate the impact of therapy following crossing. 22 Even though lesion length and plaque burden were considerably higher in the VISION CTO cohort, the efficacy and TLR rates were comparable between the CTO and non-CTO groups. These results exemplify the clinical benefits that direct OCT-guided revascularization offers for both luminal crossing and therapy.
Another area in which OCT-guided atherectomy may play an important role is the combined use of DA with drug-coated balloons (DCB). Virmani et al 23 demonstrated that drug absorption is reduced when deposited on plaque, so OCT-guided atherectomy may provide additional benefit for drug deposition as well as reduce the dissection rates seen after DCBs. In the DEFINITIVE AR trial, 24 102 patients with moderately calcified femoropopliteal lesions were treated with either DA + DCB (n=48) or DCB only (n=54). Technical success was higher and flow-limiting dissections fewer in the DA + DCB group. Stavroulakis et al 25 recently reported 21 patients with isolated popliteal artery lesions who underwent treatment with combined DA and DCB angioplasty; they observed only 1 flow-limiting dissection.
Fluoroscopy vs OCT-Guided Treatment Length
In the VISION study, an intriguing phenomenon dubbed the "diagnostic gap" was identified between lesion lengths measured with diagnostic fluoroscopy vs therapeutic OCT treatment with Pantheris. Statistically significant diagnostic gaps were measured across all lesions treated. Several studies have Ten lesions are excluded as subjects were not followed through 6 months. previously demonstrated the clinical benefits of intravascular diagnostic guidance vs fluoroscopic diagnostic guidance for revascularization in coronary disease. 26, 27 Intravascular imaging allows the interventionist the ability to combat the interand intraobserver variability typically encountered in the assessment of lesion severity. 28 Likewise, this significant difference in PAD suggests that revascularization solely based on fluoroscopic guidance frequently leads to undertreatment of disease at the proximal and distal lesion edges. The exemplary case in Figure 5B demonstrates substantial disease burden evident at the distal edge of the lesion, well beyond the fluoroscopy-diagnosed lesion boundaries (diagnostic gap). In VISION, adequate lesion edge debulking via OCT positively correlated with freedom from TLR at 6 months.
Physician Learning Curve
As with all new devices, the operator learning curve is critical in order to understand the short and long-term potential of new technologies. In the VISION study, a significant increase in the length of lesions treated was measured after 5 lesions, suggesting improved ease of use with the catheter. In addition, decreased adventitial resection and TLR rates were observed with experience. These trends may represent improvements in patient outcomes as operator usage increases. With an average 5-minute reduction in fluoroscopic time between de novo users and those with >5 cases, physicians could have an opportunity to reduce their radiation exposure without having to sacrifice their view of the patient's anatomy.
Limitations
A small sample size, moderate lesion lengths, and exclusion of restenotic lesions and moderate to severe calcium were prespecified in the VISION trial protocol in order to study this device in a relatively homogenous population. A larger cohort with more complex lesion subsets would certainly add to our understanding of the use of this technology. A short-term follow-up was used to establish procedure success rather than the device's true impact on long-term reduction of restenosis or TLR. Future studies with OCTguided atherectomy should include core laboratory-adjudicated duplex ultrasound stenosis measurements to correlate with clinically driven TLR.
Conclusion
The VISION study assessed the novel therapeutic catheter with on-board diagnostic imaging. OCT-guided atherectomy is safe and effective and has a short learning curve. The Pantheris catheter provided significant plaque excision and limited injury to the adventitia, thereby preventing dissection and perforation.
